COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00051584
Recruitment Status : Terminated
First Posted : January 15, 2003
Last Update Posted : October 24, 2011
Information provided by:
Seagen Inc.

Brief Summary:
This is an open-label, randomized phase II trial comparing treatment with a monoclonal antibody (mAb) drug immunoconjugate, SGN-15, administered weekly in combination with weekly Gemzar® (Gemcitabine) to treatment with Gemzar® alone. The primary objectives of this study are to determine the toxicity and safety profile of the combination of SGN-15 and Gemzar®, to estimate the clinical response rate and to estimate the duration of response of this combination therapy administered to patients with advanced ovarian cancer, compared to treatment with Gemzar® alone.

Condition or disease Intervention/treatment Phase
Ovarian Neoplasms Drug: SGN-15 (cBR96-Doxorubicin Immunoconjugate) Drug: Gemzar (Gemcitabine) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer
Actual Study Completion Date : May 2003

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Brief Overview of Inclusion Criteria:

  • Patients must have pathologically confirmed ovarian cancer, which is advanced or recurrent carcinoma, who have failed at least two, but no more than three prior therapies for metastatic disease
  • Patients must have > 20% Lewis-y antigen expression documented by immunohistochemistry
  • LVEF > 50% by echo or MUGA
  • Must be platinum resistant as defined by:

    • Progression while on initial platinum therapy or
    • Progression while on retreatment with initial platinum regimen or
    • Relapse < 6 months after initial therapy

Brief Overview of Exclusion Criteria:

  • Patients who have had prior therapy with Gemzar®
  • Cumulative anthracycline exposure > 300 mg/m2
  • More than three prior chemotherapy regimens for ovarian cancer (Retreatment with Taxane/Platinum after initial combination is considered only one regimen)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00051584

Layout table for location information
United States, Arizona
Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, California
Sharp Healthcare
San Diego, California, United States, 92123
California Hematology Oncology Medical Group
Torrance, California, United States, 90505
United States, Idaho
Mountain States Tumor Institute
Boise, Idaho, United States, 83712
United States, Virginia
Arlington Fairfax Hematology Oncology
Arlington, Virginia, United States, 22205
United States, Washington
Virginia Mason Medical Center
Seattle, Washington, United States, 98101
Sponsors and Collaborators
Seagen Inc.
Layout table for investigator information
Study Director: Andrew Sandler, MD Seagen Inc.
Layout table for additonal information Identifier: NCT00051584    
Obsolete Identifiers: NCT00056017
Other Study ID Numbers: SG015-0003
First Posted: January 15, 2003    Key Record Dates
Last Update Posted: October 24, 2011
Last Verified: October 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors